SEAPORT THERAPEUTICS, INC. COMMON STOCK
NASDAQ: SPTX (Seaport Therapeutics, Inc.)
Kemas kini terakhir: semalam, 11:30AM18.05
-0.27 (-1.47%)
AISkor Stockmoo
| Nilai 43% | 0.0 |
| Hutang rendah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Pulangan atas Modal info | NA |
| Trend Perolehan info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa | NA |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Kekuatan Aliran info | NA |
| Persediaan Teknikal info | NA |
| Corak Lilin info | NA |
| Sentimen 29% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Pegangan info | NA |
| Sentimen Berita info | NA |
| Wang Pintar 29% | 0.0 |
| Orang dalam menjual bersih baru-baru ini. info | |
| Institusi bersih +1.10% daripada saham dalam pemfailan 13F terkini: 47 pemegang menambah, 18 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +18.4% dari 31 Aug hingga 30 Oct 2026, 17.4 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tiada tonggak mempunyai bacaan yang jelas, jadi skor tidak berubah. | |
| Tidak dikira dalam skor | |
| Di bawah garis aliran jangka sederhana. info | |
| Harga rendah berbanding purata 52 minggunya. info | |
| Momentum jangka pendek menurun. info | |
| Harga hampir dengan paras rintangan. info | |
| Skor Akhir | 0.00 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Seaport Therapeutics, Inc. | - | - |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| SPTX | 966 M | - | - | 2.47 | 0.0 |
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
|
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 34.97% |
| % Dimiliki oleh Institusi | 72.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Trv Gp Vi, Llc | 30 Sep 2026 | 2,061,222 |
| Canada Pension Plan Investment Board | 30 Sep 2026 | 1,975,791 |
| Foresite Capital Management Vi Llc | 30 Sep 2026 | 1,779,521 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ZOHAR DAPHNE | - | 21.97 | -100,000 | -2,197,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -100,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,197,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 21.97 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ZOHAR DAPHNE | Pegawai | 10 Nov 2026 | Dibuang (-) | 100,000 | 21.97 | 2,197,000 |
Institusi
Pemilikan institusi: 71.26%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 47 | 2,485,976 |
| Berkurang | 18 | 1,817,822 |
| Baharu | 26 | 298,039 |
| Dijual habis | 6 | 372,738 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 3,733,388 | 17.4 |
| 15 Oct 2026 | 3,718,915 | 17.9 |
| 30 Sep 2026 | 3,649,879 | 8.9 |
| 15 Sep 2026 | 3,148,881 | 20.7 |
| 31 Aug 2026 | 3,152,409 | 26.0 |
| 14 Aug 2026 | 3,012,877 | 25.1 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Nov 2026 | Yahoo Finance |
How Much Upside is Left in Seaport Therapeutics, Inc (SPTX)? Wall Street Analysts Think 77.91%
The mean of analysts' price targets for Seaport Therapeutics, Inc (SPTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
| 02 Nov 2026 | Yahoo Finance |
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
BOSTON, November 02, 2026--Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress… |
| 28 Oct 2026 | Yahoo Finance |
Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
BOSTON, October 28, 2026--Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference… |
| 25 Oct 2026 | Yahoo Finance |
Is Seaport Therapeutics (SPTX) Overvalued Based On Book Value?
Seaport Therapeutics has just logged a sharp move in its share price over the past week, which naturally raises the question of whether the latest market enthusiasm lines up with what its book value supports. For anyone watching Seaport Therapeutics, the key issue now is how much of the current… |
| 25 Oct 2026 | Yahoo Finance |
Seaport Therapeutics (SPTX) Looks Cheap After Its Cash Runway Narrative Took Center Stage
Seaport Therapeutics (SPTX) has drawn fresh attention after recent trading left the shares at $20.61, with short term moves showing a mix of gains and pullbacks over the past week and month. Recent trading in Seaport Therapeutics points to choppy but generally improving sentiment, with a 7 day… |
| 09 Oct 2026 | Yahoo Finance |
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
BOSTON, October 09, 2026--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress… |
| 07 Oct 2026 | Yahoo Finance |
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON, October 07, 2026--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance… |
| 07 Oct 2026 | Yahoo Finance |
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON, October 07, 2026--Seaport Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder & Sleep Disturbance… |
| 22 Sep 2026 | Yahoo Finance |
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year. |
| 22 Sep 2026 | Yahoo Finance |
PureTech Health H1 Earnings Call Highlights
PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entit… |
| 14 Sep 2026 | Yahoo Finance |
Seaport Therapeutics to Participate in September Investor Conferences
BOSTON, September 14, 2026--Seaport Therapeutics, Inc. (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional… |
| 09 Sep 2026 | Yahoo Finance |
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON, September 09, 2026--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers… |
| 31 Aug 2026 | Yahoo Finance |
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
BOSTON, August 31, 2026--Seaport Therapeutics to present at Citi’s 2026 Biopharma Back to School Conference and participate in 21st Annual Wells Fargo Healthcare Conference… |
| 26 Aug 2026 | Yahoo Finance |
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls… |
| Papar semua | ||
Isyarat Terkini corak lilin dan silang EMA
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |